Medical management of chronic ischemic heart disease

References

• Gersh BJ, Braunwald E, Bonow RO. Chronic coronary artery disease. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia: WB Saunders, 2001: 1272–363
   Google Scholar
• Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 1999; 33(7): 2092–197 [Errata, J Am Coll Cardiol 1999; 34(1): 314 and 2001; 38(1): 296]
   Google Scholar
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324(7329): 71–86 [Erratum, Br Med J 2002; 324(7330): 141]
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494–502 [Errata, N Engl J Med 2001; 345(23): 1716 and 2001; 345(20): 1506]
   PubMed Web of Science ®Google Scholar
• A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329–39
   PubMed Web of Science ®Google Scholar
• Tsuya T, Okada M, Horie H, et al. Effect of dipyridamole at the usual oral dose on exercise-induced myocardial ischemia in stable angina pectoris. Am J Cardiol 1990; 66(3): 275–8
   Google Scholar
• van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360(9327): 109–13
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345(25): 1809–17
   PubMed Web of Science ®Google Scholar
• Tilmant PY, Lablanche JM, Thieuleux FA, et al. Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem. Am J Cardiol 1983; 52(3): 230–3
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53 [Errata, N Engl J Med 2000; 342(18): 1376 and 2000; 342(10): 748]
   PubMed Web of Science ®Google Scholar
• Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 2003; 41(1): 159–68
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383–9
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001–9
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7–22
   PubMed Web of Science ®Google Scholar
• Ronnevik PK, Silke B, Ostergaard O. Felodipine in addition to beta-adrenergic blockade for angina pectoris: a multicentre, randomized, placebo-controlled trial. Eur Heart] 1995; 16(11): 1535–41
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–72 [Erratum, JAMA 2003; 290(2): 197]
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–13 [Erratum, Lancet 2003; 361(9362): 1060]
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356(9246): 1955–64
   PubMed Web of Science ®Google Scholar
• Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial (DCCT) Research Group. Am J Cardiol 1995; 75(14): 894–903
   PubMed Web of Science ®Google Scholar
• Braunstein S. Cardiovascular disease and benefits of thiazolidinediones. In: Reappraisal of type 2 diabetes mellitus management in primary care. Minneapolis: McGraw-Hill Healthcare Information Group, 2003: 45–52 (Postgraduate Medicine: A Special Report, May 2003)
   Google Scholar
• Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104(4): 499–503
   PubMed Web of Science ®Google Scholar